MediWound Ltd. (NASDAQ:MDWD) – Research analysts at SunTrust Banks dropped their FY2017 earnings per share (EPS) estimates for MediWound in a report issued on Monday. SunTrust Banks analyst B. Nudell now anticipates that the biopharmaceutical company will post earnings per share of ($0.80) for the year, down from their previous forecast of ($0.78). SunTrust Banks currently has a “Buy” rating on the stock. SunTrust Banks also issued estimates for MediWound’s Q4 2017 earnings at ($0.21) EPS.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. The business’s revenue for the quarter was up 93.8% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/mediwound-ltd-to-post-fy2017-earnings-of-0-80-per-share-suntrust-banks-forecasts-mdwd.html.

Several other brokerages have also weighed in on MDWD. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a research report on Tuesday. Aegis reaffirmed a “buy” rating and set a $11.00 price target on shares of MediWound in a research report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. set a $10.00 price target on shares of MediWound and gave the stock a “buy” rating in a research report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $10.19.

MediWound (NASDAQ MDWD) opened at 6.70 on Thursday. The company’s market cap is $146.93 million. MediWound has a 12-month low of $4.25 and a 12-month high of $8.58. The stock’s 50 day moving average is $6.94 and its 200 day moving average is $6.46.

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN raised its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares in the last quarter. 27.32% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.